PF 4937319

Drug Profile

PF 4937319

Alternative Names: PF-04937319; PF-4937319

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Pfizer
  • Class Antihyperglycaemics; Small molecules
  • Mechanism of Action Glucokinase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Type 2 diabetes mellitus

Most Recent Events

  • 02 Feb 2016 Discontinued - Phase-I for Type-2 diabetes mellitus in Japan (PO, tablet)
  • 02 Feb 2016 Discontinued - Phase-I for Type-2 diabetes mellitus in USA (PO, controlled-release)
  • 02 Feb 2016 Discontinued - Phase-II for Type-2 diabetes mellitus in USA, Bulgaria, Canada, Hungary, India, Slovakia, Taiwan (PO, capsule)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top